Medicxi Growth I LP 的 Form 4 申報
Centessa Pharmaceuticals plc（CNTA），2026/6/24 申報
- 申報編號
- 0001193125-26-281115
- 申報時間
- 2026/6/24 16:26 ET
- 交易日
- 2026/6/24
- 申報延遲
- 當天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 6 筆非衍生性交易。交易當天就申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Medicxi Growth I LPCIK 0001690310 | 持股 10% 以上大股東 |
| Medicxi Growth Co-Invest I LPCIK 0001715578 | 持股 10% 以上大股東 |
| Medicxi Ventures Management (Jersey) LtdCIK 0001715579 | 持股 10% 以上大股東 |
| Medicxi Growth I GP LtdCIK 0001715600 | 持股 10% 以上大股東 |
| Medicxi Ventures I GP LtdCIK 0001760411 | 持股 10% 以上大股東 |
| Medicxi Ventures I LPCIK 0001760412 | 持股 10% 以上大股東 |
| Medicxi Co-Invest I LPCIK 0001760413 | 持股 10% 以上大股東 |
| Medicxi Secondary I LPCIK 0001824997 | 持股 10% 以上大股東 |
| Medicxi Secondary I GP Ltd.CIK 0001865487 | 持股 10% 以上大股東 |
| Medicxi Secondary Co-Invest I LPCIK 0001865493 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/6/24 | Ordinary Shares | S賣出處分 | −4,398,519 | –F3,F4 | – | 0 | 間接 | |
| 2026/6/24 | Ordinary Shares | S賣出處分 | −55,677 | –F3,F4 | – | 0 | 間接 | |
| 2026/6/24 | Ordinary Shares | S賣出處分 | −3,936,970 | –F3,F4 | – | 0 | 間接 | |
| 2026/6/24 | Ordinary Shares | S賣出處分 | −93,526 | –F3,F4 | – | 0 | 間接 | |
| 2026/6/24 | Ordinary Shares | S賣出處分 | −11,197,303 | –F3,F4 | – | 0 | 間接 | |
| 2026/6/24 | Ordinary Shares | S賣出處分 | −281,162 | –F3,F4 | – | 0 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F3
At the effective time of the Scheme of Arrangement (the "Effective Time"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the "Cash Consideration"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a "CVR") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS.
表 I 有 6 筆交易的價格引用這則附註。
- F4
(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Persons.
表 I 有 6 筆交易的價格引用這則附註。
備註
Medicxi Ventures (UK) LLP and Medicxi Ventures (Jersey) Limited act as sub-advisers to Index Ventures Life VI (Jersey) Limited, which acts as the adviser to Index Ventures Life VI (Jersey) LP, and as such, Index Ventures Life VI and Yucca (Jersey) SLP, each of which held Ordinary Shares prior to the transactions reported herein, and the Medicxi Funds may be deemed to be members of a "group" as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended.